Results 91 to 98 of about 85,005 (98)
Some of the next articles are maybe not open access.

Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641.

, 2020
TPS258Background: The mechanisms of action of pembro, a PD-1 inhibitor, and enza, an androgen receptor inhibitor, may be synergistic in the treatment of patients (pts) with mCRPC.
J. Graff   +3 more
semanticscholar   +1 more source

Abstract 5013: NG-641: An oncolytic T-SIGn virus targeting cancer-associated fibroblasts in the stromal microenvironment of human carcinomas

Immunology, 2019
NG-641 is a modified variant of enadenotucirev (EnAd), an Ad11p/Ad3 chimeric group B adenovirus, which retains all the functional properties of enadenotucirev while also expressing transgenes designed to target breakdown of the stromal barrier and immune
B. Champion   +14 more
semanticscholar   +1 more source

Forehead Reduction Surgery via an Anterior Hairline Pretrichial Incision in Asians: A Review of 641 Cases

Aesthetic Plastic Surgery, 2021
Soo Hyang Lee   +3 more
semanticscholar   +1 more source

Long non-coding RNA OIP5-AS1 promotes proliferation of gastric cancer cells by targeting miR-641.

European Review for Medical and Pharmacological Sciences, 2019
Wang Lw   +5 more
semanticscholar   +1 more source

Suppression of miR-628-3p and miR-641 is involved in rifampin-mediated CYP3A4 induction in HepaRG cells.

Pharmacogenomics (London), 2017
Liang Yan   +6 more
semanticscholar   +1 more source

Intronic miRNA-641 controls its host Gene's pathway PI3K/AKT and this relationship is dysfunctional in glioblastoma multiforme.

Biochemical and Biophysical Research Communications - BBRC, 2017
L. C. Hinske   +5 more
semanticscholar   +1 more source

Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation

Leukemia and Lymphoma, 2015
Zheng Zhou   +7 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy